CFM
CORT icon

Catalyst Funds Management’s Corcept Therapeutics CORT Stock Holding History

Catalyst Funds Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,800
Closed -$1.6M – 523
2025
Q2 		$1.6M Buy
+21,800
New +$1.58M 0.44% 62
2024
Q4 		– Sell
-1,100
Closed -$50.9K – 536
2024
Q3 		$50.9K Buy
+1,100
New +$39.1K 0.01% 787

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Catalyst Funds Management's CORT Position: Q3 2025 in Review

Catalyst Funds Management sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 21,800 shares — an estimated $1.6M sold.

Catalyst Funds Management first reported a position in CORT in Q3 2024 and held it in 2 quarters. The position peaked at $1.6M in Q2 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Catalyst Funds Management reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 21,800 Corcept Therapeutics shares in Q3 2025, an estimated $1.6M.
  • Catalyst Funds Management first reported a position in Corcept Therapeutics in Q3 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Corcept Therapeutics position peaked at $1.6M in Q2 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Catalyst Funds Management's 13F filing for Q3 2025, filed 12 Nov 2025.